Tags : Clinical Testing

COVID-19 Pharma

Aldeyra Therapeutics to Advance ADX-1612 to Clinical Testing and Provides

Shots: Aldeyra has reported the planned advancement of ADX-1612 (HSP90 inhibitor) to clinical testing for COVID-19, and provided an update on ADX-629 (RASP inhibitor) for COVID-19 and other inflammatory diseases ADX-1612 has demonstrated nanomolar potency like or greater than Gilead’s remdesivir in an in vitro model and acts by inhibiting the proteins associated with viral […]Read More

COVID-19 Pharma

Eli Lilly Signs a Clinical Trial Collaboration with NIH to

Shots: The clinical research commences in NIH-led Adaptive COVID-19 Treatment Trial and will evaluate the efficacy and safety of baricitinib for hospitalized patients diagnosed with COVID-19, initiating this month in the US with a planned expansion to additional sites including EU and Asia Additionally, Lilly will advance its LY3127804 (mAb against Ang2) to P-II study […]Read More